<DOC>
	<DOCNO>NCT00429260</DOCNO>
	<brief_summary>The primary objective evaluate safety tolerability abrupt discontinuation saredutant 1 week outpatient depression complete 8 week treatment saredutant 100 mg daily . The secondary objective evaluate safety tolerability 8 week open-label treatment saredutant 100 mg daily outpatient depression .</brief_summary>
	<brief_title>A Study Evaluating Safety Tolerability Abrupt Discontinuation Saredutant Patients With Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>Diagnosis major depressive disorder , single recurrent episode , define Diagnostic Statistical Manual Mental Disorders DSMIV criterion Total score &lt; 22 MontgomeryAsberg Depression Rating Scale ( MADRS ) . Duration current depressive episode less 1 month great 2 year . Total score &lt; 25 Mini Mental State Examination ( elderly patient â‰¥65 year ) . Patients history presence bipolar disorder psychotic disorder . Patients alcohol dependence abuse substance dependence abuse past 6 month except nicotine caffeine dependence . Patients use follow prior entry : benzodiazepine sedativehypnotics 2 day per week within 1 month , antipsychotic within 1 month , fluoxetine within 1 month , monoamine oxidase inhibitor within 2 week , antidepressant , anxiolytic , moodstabilizer ( lithium , anticonvulsant ) within 1 week . The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>depression</keyword>
	<keyword>antidepressive agent</keyword>
</DOC>